Health Effects of Abdominal Liposuction in Newly Diagnosed Type 2 Diabetes

Abstract

Background Diabetes Mellitus (DM) is a metabolic disorder characterized by the presence of chronic hyperglycaemia accompanied by greater or lesser impairment in the metabolism of carbohydrates, lipids and proteins. DM is probably one of the oldest diseases known to man. It was first reported in Egyptian manuscript about 3000 years ago. In 1936, the distinction between type 1 and type 2 DM was clearly made. Type 2 DM was first described as a component of metabolic syndrome in 1988. The origin and aetiology of DM can vary greatly but always include defects in either insulin secretion or response or in both at some point in the course of disease. Objective The aim of this study is to evaluate the effectiveness of abdominal liposuction in improving quality of life in newly diagnosed uncomplicated type 2 diabetic patients. Methodology This study will take place in plastic Surgery Department, Port Said general Hospital. As total number of cases satisfying inclusion criteria not exceed 6 cases per month during the study period (3 months) the total sample 3x6=18 cases all will be included as comprehensive sample. Results In our study, the mean FPG was 163 ± 22 mg/dl preoperatively. At three months after surgery, it was 162 ± 29 mg/dl, but at six months after surgery, it was 147 ± 28 mg/dl. The mean PPBG was 218 ± 40 mg/dl preoperatively. At three months after surgery, it was 216 ± 40 mg/dl, but at six months after surgery, it was 200 ± 34 mg/dl. The mean HbA1c percentage was 8 ± 0.8% preoperatively. At three months after surgery, it was 7.7 ± 0.8%, but at six months after surgery, it was 7.6 ± 0.8%. The mean triglyceride level was 180 ± 48 preoperatively. At three months after surgery, it was 162 ± 41, but at six months after surgery, it was 159 ± 49. The mean cholesterol was 207 ± 42 preoperatively. At three months after surgery, it was 197 ± 52, but at six months after surgery, it was 189 ± 41. The HOMA-IR was 3 ± 0.7 preoperatively. At three months after surgery, it was 2.8 ± 0.7, but at six months after surgery, it was 2.8 ± 0.7. All the laboratory investigations change over time among the studied patients were not statistically significant. Conclusion So, we can conclude that large-volume abdominal liposuction should not, by itself, be considered a clinical therapy for type 2 diabetes mellitus. Aspiration of large amounts of subcutaneous abdominal fat in diabetic patients, despite having cosmetic benefits, It does not significantly improve insulin sensitivity through altering serum levels of obesity markers. Therefore, the procedure is safe and may could successfully help diabetic subjects to reduce their potential metabolic risks. Therefore, abdominal Liposuction is effective scarless operation for subcutaneous adipose fatty tissue reduction.